Skip to main content
رجوع
GYRE logo

Gyre Therapeutics, Inc.

جودة البيانات: 100%
GYRE
NASDAQ Healthcare Biotechnology
KWD 6.94
▼ KWD 0.10 (-1.42%)
القيمة السوقية: 630.78M
نطاق اليوم
KWD 6.91 KWD 7.24
نطاق 52 أسبوعًا
KWD 6.11 KWD 11.78
حجم التداول
115,642
متوسط 50 يوم / 200 يوم
KWD 7.92 / KWD 7.75
الإغلاق السابق
KWD 7.04

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 125.5 0.3
P/B 6.0 2.9
ROE % 5.9 3.7
Net Margin % 4.3 3.8
Rev Growth 5Y % 99.7 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 16.000 +130.5%
ربحية السهم المستقبلية
-KWD 0.320
الإيرادات المقدّرة
140 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 0.250
KWD 0.207 – KWD 0.310
310 M 1
FY2029 KWD 0.110
KWD 0.091 – KWD 0.137
270 M 1
FY2028 KWD 1.710
KWD 1.418 – KWD 2.123
440 M 1

النقاط الرئيسية

Revenue grew 99.65% annually over 5 years — strong growth
Earnings declined -58.40% over the past year
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -180,000.0
P/E of 125.48 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 89.41%

النمو

Revenue Growth (5Y)
99.65%
Revenue (1Y)10.24%
Earnings (1Y)-58.40%
FCF Growth (3Y)N/A

الجودة

Return on Equity
5.94%
ROIC8.05%
Net Margin4.31%
Op. Margin9.85%

الأمان

Debt / Equity
0.01
Current Ratio5.60
Interest Coverage0.00

التقييم

P/E Ratio
125.48
P/B Ratio5.95
EV/EBITDA51.77
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.24% Revenue Growth (3Y) 1.37%
Earnings Growth (1Y) -58.40% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 99.65% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 116.59M Net Income (TTM) 5.03M
ROE 5.94% ROA 3.03%
Gross Margin 95.35% Operating Margin 9.85%
Net Margin 4.31% Free Cash Flow (TTM) -180,000.0
ROIC 8.05% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 5.60
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 125.48 P/B Ratio 5.95
P/S Ratio 5.41 PEG Ratio -2.10
EV/EBITDA 51.77 Dividend Yield 0.00%
Market Cap 630.78M Enterprise Value 594.65M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 116.59M 105.76M 113.45M 102.29M 7.34M
Net Income 5.03M 12.09M -92.93M 2.30M -87.93M
EPS (Diluted) 0.02 0.05 -1.41 0.03 -2.87
Gross Profit 111.17M 101.87M 108.81M 97.50M -332,000.0
Operating Income 11.49M 16.16M -67.23M 9.20M -83.73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 166.13M 125.41M 116.54M 84.75M 55.66M
Total Liabilities 23.85M 27.00M 102.59M 12.54M 14.57M
Shareholders' Equity 106.03M 63.32M -15.83M 42.52M 41.09M
Total Debt 939,000.0 1.60M 409,000.0 613,000.0 2.39M
Cash & Equivalents 37.07M 11.81M 33.51M 25.18M 44.35M
Current Assets 102.37M 64.79M 57.22M 49.65M 51.48M
Current Liabilities 18.29M 19.52M 20.05M 12.24M 14.17M